That information is widely
open for debate and I do not agree with the way it was stated. The 1.6 months statement above is about
localized prostate cancer (John did say that) and the source is retrospective Level III data (John did not state this) pulled from a pool of select patients whom we know little about
their protocols. While the benefit looks small, it's important to note when stating this that most of these men, virtually all over the age of 65 with localized prostate cancer will die of something else many years later. And that statement does not apply to your advanced case with treatment protocol studies of a much higher level of certainty showing good treatment benefit in intermediate and advanced cases. I had to go back and look at your data and you absolutely are on the right track with your treatment. And there's plenty of ammunition in your arsenal.
1. Chemotherapy prior to 2004 for prostate cancer was strictly palliative using mitoxantrone. The FDA approved TAX-327 after phase III Level I clinical trials showed that TAX-327 extended the lives of men 19 months versus placebo. The median age in that trial was 70yo with advanced metastatic disease. The drug today is Taxotere (docetaxel) and is widely used with life extension benefits.
2. Provenge showed 4 mos life extension and was primarily effective in 70yo+ men after they had chemotherapy and had already had compromised immune systems.
3. Zytiga. Same story, after chemo and in men that were way along in their disease, it still showed survival benefit to the point that the FDA approved removing the placebo arm mid-trial.
4. Xtandi and TAK700. Again same story. TAK-700 is set for release this year and is already released for thyroid cancer and it's phase III trial showed life extension.
I'll stop with a list I can grow. The fact is that for men like yourself, at age 72, we are in a great era of new hormonal and imuno-drugs. And the principle benefactors of these drugs in trial were older men. What we are waiting to see is how well these drugs work BEFORE chemotherapy and before the disease becomes non-responsive to it. I believe we'll continue to see improvement in benefit for those listed, and we'll see more new drugs soon on the market that will continue to extend lives and reduce prostate cancer specific mortality rates.
Post Edited (TC-LasVegas) : 3/15/2013 11:28:34 PM (GMT-6)